Novo Nordisk stock faces FDA warning over rare vision risk

Published on 11/11/2026 at 12:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock faces a new regulatory issue after the FDA ordered vision-risk warnings for Wegovy and other GLP-1 medicines. The company disputes a proven link.

FDA warning raises a new risk issue

The FDA is requiring all GLP-1 manufacturers to add information on a potential NAION risk to product labeling.
Novo Nordisk disputes a proven cause-and-effect relationship and continues to defend the benefit-risk profile of its medicines.
The US action follows earlier European label changes and ongoing litigation over alleged vision damage.

Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

The US Food and Drug Administration is requiring new safety language for GLP-1 medicines, including Novo Nordisk's Wegovy and Ozempic, after identifying a potential increased risk of the rare eye condition non-arteritic anterior ischemic optic neuropathy, or NAION. Novo Nordisk stock traded at 36.57 euros on Lang & Schwarz at 12:04 CET on Wednesday, November 11.

According to Becker's Hospital Review, the FDA announced the labeling action on November 9. NAION can cause sudden, painless vision loss in one eye and may leave permanent impairment. The agency said it considered clinical-trial, animal, postmarket, observational and case-report evidence.

Rare risk adds pressure to GLP-1 portfolio

The FDA action applies across the GLP-1 class, making it broader than a product-specific measure against Novo Nordisk. The company had already added a NAION warning to European Wegovy and Ozempic labels in June, with the condition described as occurring in up to 1 in 10,000 patients.

Novo Nordisk has rejected a confirmed causal relationship between semaglutide and NAION. A company spokesperson said in September that the totality of the evidence did not establish causation, while the company maintained confidence in the benefit-risk profile of its GLP-1 medicines.

The regulatory decision comes as litigation expands. Becker's Hospital Review reported that at least 4,000 consolidated claims alleging GLP-1-related vision loss had been filed as of September. The report also cited a 2025 study of nearly 175,000 people with diabetes that found the risk of NAION more than doubled after two years of semaglutide treatment compared with other diabetes medicines. These findings describe an association and do not establish that the drug caused the condition.

What the warning means for investors

For Novo Nordisk, the label change adds a safety and communication burden to a portfolio that remains central to the company's obesity and diabetes strategy. The warning does not amount to a finding that Wegovy or Ozempic causes NAION, but it gives prescribers and patients another risk factor to weigh when treatment decisions are made.

The next investor focus remains prescription momentum, competitive positioning and the company's response to the US labeling change. A broader European trading context is available in current market reports.

More company coverage is available in more news and analyses on Novo Nordisk stock.